Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Apr 25 2025

0mins

BOLT-7.45%

Should l Buy BOLT?

Source: Newsfilter

Clinical Study Results: BDC-3042, a novel immunotherapy developed by Bolt Biotherapeutics, demonstrated a favorable safety profile and biological activity in a Phase 1 clinical trial, with no serious adverse events reported and signs of anti-tumor activity in patients with various cancers.
Future Development Plans: The company is seeking partnerships to accelerate the development of BDC-3042, which targets dectin-2 on tumor-associated macrophages, and aims to explore its potential in combination with other therapies for improved patient outcomes.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy BOLT?" and start using high-conviction signals backed by rigorous historical data.

BOLT

$5.34+Infinity%1D

Analyst Views on BOLT

Wall Street analysts forecast BOLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BOLT is 41.00 USD with a low forecast of 7.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Analyst Rating

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 5.770

Low

7.00

Averages

41.00

High

75.00

Current: 5.770

Low

7.00

Averages

41.00

High

75.00

H.C. Wainwright

NULL -> Buy

initiated

2025-10-20

Reason

H.C. Wainwright

Price Target

AI Analysis

2025-10-20

initiated

NULL -> Buy

Reason

H.C. Wainwright assumed coverage of Bolt Biotherapeutics with a Buy rating and $7 price target. The company's lead asset, BDC-4182, differentiates itself relative to antibody-drug conjugates since the payload is an immune-stimulatory agent instead of a cytotoxic warhead, the analyst tells investors in a research note. The firm says initial clinical results for BDC-4182 are expected in Q3 of 2026.

Lake Street

Chad Messer

Buy

maintain

$4 -> $75

2025-08-15

Reason

Lake Street

Chad Messer

Price Target

$4 -> $75

2025-08-15

maintain

Buy

Reason

Lake Street analyst Chad Messer raised the firm's price target on Bolt Biotherapeutics to $75 from $4 and keeps a Buy rating on the shares after Bolt ended Q2 with $48.5M in cash and reiterated its cash runway through mid-2026. The company completed a 20:1 reverse stock split to regain compliance with Nasdaq listing requirements in June, notes the analyst, who adjusted the firm's target to account for the reverse split.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BOLT

Unlock Now

About BOLT

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Bolt Announces Q3 2025 Financial Results and Updates on Oncology Pipeline Advancements

Nov 13 2025NASDAQ.COM

Company Overview: Bolt Biotherapeutics, Inc. reported its Q3 2025 financial results, highlighting its focus on developing immunotherapies for cancer through its proprietary Boltbody ISAC platform, which includes two clinical-stage candidates, BDC-3042 and BDC-4182.
Clinical Trials Update: BDC-3042, targeting tumor-associated macrophages, has shown early signs of immune activation in a Phase 1 study, while BDC-4182 is being evaluated for gastric and gastroesophageal cancers, with initial data expected in Q3 2026.
Financial Performance: The company reported a narrowed net loss of $7.1 million for Q3 2025, a significant improvement from the previous year, attributed to reduced R&D and G&A costs following a corporate restructuring.
Stock Performance: Bolt's stock has fluctuated between $4.42 and $13 over the past year, closing at $4.69 recently, with a slight increase in overnight trading.

HC Wainwright & Co. Initiates Coverage on Bolt Biotherapeutics with a Buy Rating and Sets Price Target at $7

Oct 20 2025Benzinga

Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Community and Exclusivity: Joining Benzinga Pro connects traders with over 10,000 members and provides access to exclusive stories and insights from Benzinga reporters.